These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22080962)

  • 1. Self-reported mammography use following BRCA1/2 genetic testing may be overestimated.
    Larouche G; Bouchard K; Chiquette J; Desbiens C; Simard J; Dorval M
    Fam Cancer; 2012 Mar; 11(1):27-32. PubMed ID: 22080962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
    Larouche G; Chiquette J; Pelletier S; Simard J; Dorval M
    Fam Cancer; 2017 Jan; 16(1):35-40. PubMed ID: 27554086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.
    Phi XA; Houssami N; Obdeijn IM; Warner E; Sardanelli F; Leach MO; Riedl CC; Trop I; Tilanus-Linthorst MM; Mandel R; Santoro F; Kwan-Lim G; Helbich TH; de Koning HJ; Van den Heuvel ER; de Bock GH
    J Clin Oncol; 2015 Feb; 33(4):349-56. PubMed ID: 25534390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
    Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
    Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening adherence in BRCA1/2 families is associated with primary physicians' behavior.
    Tinley ST; Houfek J; Watson P; Wenzel L; Clark MB; Coughlin S; Lynch HT
    Am J Med Genet A; 2004 Feb; 125A(1):5-11. PubMed ID: 14755459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
    Narod SA; Lubinski J; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Rosen B; Kim-Sing C; Isaacs C; Domchek S; Sun P;
    Lancet Oncol; 2006 May; 7(5):402-6. PubMed ID: 16648044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
    Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers.
    Pijpe A; Mulder RL; Manders P; ; van Leeuwen FE; Rookus MA
    J Clin Epidemiol; 2011 Dec; 64(12):1434-43. PubMed ID: 21764559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
    Larouche G; Chiquette J; Plante M; Pelletier S; Simard J; Dorval M
    Can Assoc Radiol J; 2016 Nov; 67(4):308-312. PubMed ID: 27318890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Liljegren A; von Wachenfeldt A; Azavedo E; Eloranta S; Grundström H; Ståhlbom AK; Sundbom A; Sundén P; Svane G; Ulitzsch D; Arver B
    Breast Cancer Res Treat; 2018 Apr; 168(3):655-666. PubMed ID: 29318406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
    Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
    Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    Vreemann S; van Zelst JCM; Schlooz-Vries M; Bult P; Hoogerbrugge N; Karssemeijer N; Gubern-Mérida A; Mann RM
    Breast Cancer Res; 2018 Aug; 20(1):84. PubMed ID: 30075794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring adherence to mammography screening recommendations among low-income women.
    Armstrong K; Long JA; Shea JA
    Prev Med; 2004 Jun; 38(6):754-60. PubMed ID: 15193895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    McGuinness JE; Trivedi MS; Silverman T; Marte A; Mata J; Kukafka R; Crew KD
    Cancer Genet; 2019 Jun; 235-236():72-76. PubMed ID: 31078448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.
    Botkin JR; Smith KR; Croyle RT; Baty BJ; Wylie JE; Dutson D; Chan A; Hamann HA; Lerman C; McDonald J; Venne V; Ward JH; Lyon E
    Am J Med Genet A; 2003 Apr; 118A(3):201-9. PubMed ID: 12673648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening.
    McInerney-Leo A; Hadley D; Kase RG; Giambarresi TR; Struewing JP; Biesecker BB
    Am J Med Genet A; 2006 Oct; 140(20):2198-206. PubMed ID: 16969872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
    Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.